Vyvgart Hytrulo Sjögren's Futility Erases $1.4B Bet, Spares gMG and CIDP Core
Clinical Trial Updates

Vyvgart Hytrulo Sjögren's Futility Erases $1.4B Bet, Spares gMG and CIDP Core

Published : 17 Nov 2026

The Overview
Argenx has decided to discontinue the development of Vyvgart Hytrulo for Sjögren’s disease following an interim review of the Phase 3 UNITY study. An independent data monitoring board determined the drug would not meet the primary endpoint of improvement in systemic disease. This setback removes a significant expansion opportunity for Vyvgart Hytrulo, which analysts had projected could achieve peak sales of $1.4 billion in this indication. Vyvgart Hytrulo is currently approved by the FDA for generalized myasthenia gravis (2023) and chronic inflammatory demyelinating polyneuropathy (2024), with other programs for its active ingredient, efgartigimod, ongoing.
Knolens Analysis

Argenx halted Vyvgart Hytrulo in Sjögren's disease after independent interim review of Phase 3 UNITY concluded it would not meet the primary endpoint of improvement in systemic disease, erasing a $1.4 billion peak sales expansion while leaving FDA approvals in generalized myasthenia gravis (2023) and chronic inflammatory demyelinating polyneuropathy (2024) intact. The failure contrasts with randomized Phase 2 RHO proof-of-concept where intravenous efgartigimod 10 mg/kg showed CRESS response of 45.5% versus 11.1% and cSTAR ≥5 of 54.5% versus 33.3% in only 31 efficacy-evaluable patients with no formal hypothesis tested. [1] Competitive pressure intensifies as B-cell-targeted ianalumab and telitacicept reported positive Phase 3 results with ESSDAI improvements, while FcRn peers nipocalimab and IMVT-1402 remain investigational in Sjögren's disease without disclosed pivotal data. [2][3] Payer resistance frames any re-entry: NICE TA1069 did not recommend efgartigimod for AChR-positive gMG, the Danish Medicines Council did not recommend add-on use citing temporary effect and unreasonably high price, and G-BA reassessment in 2024 found additional benefit not proven versus eculizumab or ravulizumab. No filing is expected on this dataset, and FcRn efficacy in antibody-driven neuromuscular disease does not translate to systemic Sjögren's disease.

UNITY interim futility on systemic disease outweighs small RHO Phase 2 CRESS signal in 31 patients without formal testing.

At a Glance
IndicationSjögren’s disease
DrugVyvgart Hytrulo
Mechanism of ActionFcRn inhibitor
CompanyArgenx
Trial PhasePhase 3
Trial AcronymUNITY
CategoryClinical Trial Event
Sub CategoryTrial Halted / Terminated
Therapeutic AreaImmunology
Primary Endpointimprovement in systemic disease
Peak Sales Model$1.4 billion
Approved Indication 1generalized myasthenia gravis
Approved Indication 2chronic inflammatory demyelinating polyneuropathy
Approval Year 12023
Approval Year 22024
Ongoing ProgramsGraves’ disease, systemic sclerosis, immune thrombocytopenia
Trial Outcomefutility finding
Regulatory AgencyFDA
Phase 2 Data SourcePhase 2 RHO trial, published in April

Argenx Halts Sjögren’s Program for Vyvgart Hytrulo After Futility

Argenx has decided to discontinue the development of Vyvgart Hytrulo for Sjögren’s disease following an interim review of the Phase 3 UNITY study. An independent data monitoring board determined the drug would not meet the primary endpoint of improvement in systemic disease. This setback removes a significant expansion opportunity for Vyvgart Hytrulo, which analysts had projected could achieve peak sales of $1.4 billion in this indication. Vyvgart Hytrulo is currently approved by the FDA for generalized myasthenia gravis (2023) and chronic inflammatory demyelinating polyneuropathy (2024), with other programs for its active ingredient, efgartigimod, ongoing.

  • Argenx ceased development of Vyvgart Hytrulo in Sjögren’s disease after an independent data monitoring board concluded that the Phase 3 UNITY study would not achieve its primary endpoint of systemic disease improvement. This decision was based on an interim review, leading to the discontinuation of the program.
  • The discontinuation of the Sjögren’s disease program for Vyvgart Hytrulo eliminates a key potential blockbuster expansion, with analysts having previously modeled peak sales of $1.4 billion for this specific indication. This represents a significant financial setback for the drug's future growth prospects.
  • Despite the Sjögren’s setback, Vyvgart Hytrulo remains approved by the FDA for generalized myasthenia gravis (2023) and chronic inflammatory demyelinating polyneuropathy (2024). Argenx continues to advance programs for efgartigimod, its active ingredient, in other autoimmune conditions such as Graves’ disease, systemic sclerosis, and immune thrombocytopenia.

Unpacking Vyvgart Hytrulo's Sjögren's Phase 3 Futility

Recent randomized and observational studies in Sjögren's disease have evaluated targeted immunotherapies in patients with active systemic disease. Efficacy assessment has centered on the EULAR Sjögren's Syndrome Disease Activity Index and Patient Reported Index, with safety evaluated through adverse events and serious adverse events.

  • DAHLIAS – nipocalimab: This phase 2, double-blind, multicentre trial randomized participants with moderate-to-severe, active Sjögren's disease to intravenous nipocalimab 5 mg/kg, intravenous nipocalimab 15 mg/kg, or placebo every 2 weeks for 22 weeks. The primary endpoint was change from baseline in ClinESSDAI score at week 24, with a least squares mean difference versus placebo of -2·65, 90% CI -4·03 to -1·28; p=0·0018 for 15 mg/kg and -0·34, -1·71 to 1·03; p=0·68 for 5 mg/kg. The safety profile of nipocalimab was comparable, for both doses, with that of placebo, with generally similar rates of adverse events and serious adverse events across groups.

  • Randomized, placebo-controlled, phase 2b dose-ranging study – ianalumab: Patients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks until week 24. By week 52, efficacy was sustained in patients who continued 300 mg, with EULAR Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index, patient global assessment, and physician global assessment change from week 24 of -1.45, -0.46, -4.69, and -6.86, respectively. Treatment-emergent adverse events were not dose-dependent, except for injection-site reactions, with cases of decreased neutrophil counts observed in three patients during posttreatment follow-up.

  • PORTRESS – rituximab: This multicentre, retrospective, observational study included 69 adult patients treated with rituximab and registered in PORTRESS, the Portuguese Registry of Sjögren's disease. ESSDAI significantly decreased from 11(6-22) to 4(0-8) at 12 months (p<.001), with a clinically meaningful response (ΔESSDAI ≥3) achieved in 74% of patients, and median glucocorticoid dose decreased from 5.0(0-12.5) to 0(0-5.0) mg/day (p<.001). Rituximab was well tolerated, with mild-to-moderate adverse events reported in 13.0% of cases and treatment discontinued within the first 12 months in 20.3% of patients, mainly due to adverse events (7.2%).

The Intricate Challenges of Treating Sjögren's Disease

The therapeutic management of Sjögren syndrome has not changed substantially in recent decades, with treatment decisions remaining challenging in clinical practice. No immunomodulatory drug has been approved for primary Sjögren's syndrome, and there is no specific therapeutic target beyond the relief of symptoms as the most important goal.

  • Conventional therapy with moisturizers, pilocarpine, cevimeline, local cyclosporine, and hydroxychloroquine remains the basis for treatment but does not modify the course of the disease, while treating the associated salivary gland hypofunction has been challenging to clinicians.

  • Evidence from controlled trials supports benefits for pilocarpine and cevimeline for sicca features and topical ocular 0.05% cyclosporine for moderate or severe dry eye, with topical treatments for dry mouth and dry eye reported as safe and effective, while limited data from RCTs are available to guide systemic therapies.

  • Double-blind prospective trials of traditional disease-modifying antirheumatic drugs and biologics have failed because they have not improved benign symptoms, the major cause of lowered quality of life; RCTs using infliximab, anakinra and baminercept found no placebo-differences for the primary outcomes, two placebo-controlled trials of infliximab and etanercept did not achieve the primary outcome (a composite visual analog scale measuring joint pain, fatigue, and dryness), and the use of tocilizumab did not improve systemic involvement and symptoms over 24 weeks of treatment compared with placebo.

  • The two largest RCTs randomised 255 patients to receive rituximab or placebo and reported no significant results in the primary outcome (VAS composite), while prospective studies suggested efficacy in systemic disease; rituximab has proven effective in patients with associated mixed cryoglobulinemia, parotid gland swelling, lymphocytic interstitial pneumonitis, thrombocytopenia, and other manifestations, but there were few of these patients in the trials required for FDA approval.

  • Assessment complicates management because the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) remains the standard for systemic activity while the ESSPRI captures subjective symptom burden, they do not evaluate the same manifestations and may therefore respond differently to treatment, and assessment of damage, defined as irreversible sequelae, remains an unmet need.

  • Adverse events were common, with sialorrhoea and nausea as the most common side-effects of pilocarpine, infusion-related reactions and serum sickness remaining possible with rituximab, and QT prolongation and secondary arrhythmia documented as a serious side effect of therapy with hydroxychloroquine.

Frequently Asked Questions

How does FcRn inhibition address the underlying pathology of Sjögren's disease?
FcRn inhibitors reduce circulating levels of pathogenic immunoglobulin G (IgG) autoantibodies by blocking the neonatal Fc receptor, which is responsible for recycling IgG. In Sjögren's disease, autoantibodies play a crucial role in glandular destruction and systemic inflammation. By lowering these autoantibody levels, FcRn inhibition aims to mitigate the autoimmune attack on exocrine glands and other affected tissues.
What are the current therapeutic challenges and unmet needs in managing Sjögren's disease?
Current Sjögren's disease management primarily focuses on symptomatic relief, with limited approved disease-modifying therapies for systemic manifestations. Patients often experience persistent debilitating symptoms like severe dry eyes and mouth, fatigue, and pain, significantly impacting their quality of life. There is a critical need for treatments that can effectively target the underlying autoimmune pathology and prevent disease progression.
What is the rationale for investigating Vyvgart Hytrulo in Sjögren's disease?
Vyvgart Hytrulo, an FcRn blocker, is being investigated in Sjögren's disease due to its mechanism of reducing pathogenic IgG autoantibodies. Sjögren's is an autoimmune condition characterized by the production of autoantibodies that target exocrine glands and other organs. Modulating these autoantibody levels could potentially interrupt the inflammatory cascade and improve disease activity.
How might FcRn inhibitors like Vyvgart Hytrulo differentiate from existing Sjögren's disease treatments?
FcRn inhibitors offer a targeted approach by specifically reducing pathogenic IgG autoantibodies, which are central to Sjögren's pathophysiology. This mechanism differs from current symptomatic treatments or broad immunosuppressants, potentially offering a more precise intervention. The aim is to provide disease modification beyond symptom management, addressing the systemic autoimmune burden more directly.

References

  1. [1] Brito-Zerón P, Retamozo S et al.. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD open. 2019. 31749986
  2. [2] Chaudhury NM, Shirlaw P et al.. Changes in Saliva Rheological Properties and Mucin Glycosylation in Dry Mouth. Journal of dental research. 2015 Dec. 26446936
  3. [3] O'Neill ID, Scully C. Biologics in oral medicine: Sjogren syndrome. Oral diseases. 2013 Mar. 22497865
  4. [4] Devauchelle-Pensec V, Mariette X et al.. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Annals of internal medicine. 2014 Feb 18. 24727841
  5. [5] Ramos-Casals M, Tzioufas AG et al.. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010 Jul 28. 20664046
  6. [6] Yang M, Lu Y et al.. Efficacy and safety of pharmacological treatment for Sjögren's disease: a network meta-analysis. Zeitschrift fur Rheumatologie. 2026 Oct. 42113283
  7. [7] Jiang Q, Zhang H et al.. Acupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial. BMC complementary and alternative medicine. 2017 Jan 19. 28103850
  8. [8] Saraux A, Pers JO et al.. Treatment of primary Sjögren syndrome. Nature reviews. Rheumatology. 2016 Aug. 27411907
  9. [9] Pérez-Neri I, Sandoval H et al.. Central and peripheral mechanisms of pain in fibromyalgia: scoping review protocol. Rheumatology international. 2023 Apr. 36635578
  10. [10] Suzuki T, Yamada S et al.. Potential stratification of TAFRO syndrome by anti-SS-A antibodies status and therapeutic response to rituximab. RMD open. 2026 May 21. 42167888
  11. [11] Baldini C, Fulvio G et al.. Update on the pathophysiology and treatment of primary Sjögren syndrome. Nature reviews. Rheumatology. 2024 Aug. 38982205
  12. [12] Cifuentes M, Del Barrio-Díaz P et al.. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial. The British journal of dermatology. 2018 Nov. 29432648
  13. [13] Arends S, Verstappen GM et al.. Why do drug treatments fail in Sjögren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy. Expert review of clinical immunology. 2023 Jul-Dec. 37551702
  14. [14] Lee MS, Shin BC et al.. Acupuncture for treating dry eye: a systematic review. Acta ophthalmologica. 2011 Mar. 20337604
  15. [15] Chen Q, Chen X et al.. A relatively rare traditional Chinese medicine pattern of primary Sjögren syndrome: A case report. Medicine. 2024 Apr 12. 38608118
  16. [16] Yayla ME, Şahin Eroğlu D et al.. Indications and risk factors for hospitalization in patients with primary Sjögren syndrome: experience from a tertiary center in Turkey. Clinical rheumatology. 2022 May. 34988683
  17. [17] Bachiller-Corral J, Boteanu A et al.. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. The Journal of rheumatology. 2021 Jul. 33722949
  18. [18] Ning Y, Zhang X et al.. [Sjögren disease complicated by primary breast lymphoma: A case report]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2025 Aug 18. 40754924
  19. [19] López-García JS, García-Lozano I. Use of containers with sterilizing filter in autologous serum eyedrops. Ophthalmology. 2012 Nov. 22867978
  20. [20] Prelipcean CC, Mihai C et al.. Extragastric manifestations of Helicobacter pylori infection. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2007 Jul-Sep. 18293684

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts